Advertisement

In COPD, Beta-Blockers Lower Mortality After MI — Physician’s First Watch

Medical News |
November 26, 2013

In COPD, Beta-Blockers Lower Mortality After MI

By Joe Elia

Beta-blocker use, sometimes limited in patients with chronic obstructive pulmonary disease because of worry over inducing bronchospasm, offers a survival advantage after myocardial infarction in such patients, a BMJ study shows.

Researchers used U.K. national databases to examine outcomes in 1063 patients with COPD who were hospitalized after sustaining a first MI.

Patients prescribed beta-blockers during their hospital stay showed a mortality hazard ratio of 0.50 relative to those not prescribed them. Patients already on the drugs before the MI also showed a significant survival advantage (HR, 0.59).

The authors note that only about one third of the patients were prescribed a beta-blocker during their hospitalization, adding that use of the drugs in the U.S. has increased in recent years and now exceeds 90% of such patients.

Reader Comments (3)

namita tiwari Resident, Surgery, General

This is a good observational study. I have seen the use of bb on patients with COPD but who had high BP and tachycardia and the use of BB (although low does) significantly helped these patients and there was no complication of bronchospasm noticed.
However, i think it is dose related.

noel Kayo Resident, Internal Medicine, University cardiovascular research

This is a very good observational study. We hope to see the same with post MI cocaine.

Miguel Gambetta Physician, Cardiology

Dose prescribed? Was it "low"? Whatever dose, it was good for these patients.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement